174. Deputy Noel Grealish asked the Minister for Health the status of the review of nivolumab; if this drug will be licensed here; the timeframe for completion of the review of the cost effectiveness of this drug in view of the fact that the manufacturer discontinued a compassionate access programme on 30 June 2016; and if he will make a statement on the matter. [8873/17]

Summary

174. Deputy Noel Grealish asked the Minister for Health the status of the review of nivolumab; if this drug will be licensed here; the timeframe for completion of the review of the cost effectiveness of this drug in view of the fact that the manufacturer discontinued a compassionate access programme on 30 June 2016; and if he will make a statement on the matter. [8873/17]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 22 February 2017

   Medicinal Products Reimbursement

   174. Deputy Noel Grealish asked the Minister for Health the status of the review of nivolumab; if this drug will be licensed here; the timeframe for completion of the review of the cost effectiveness of this drug in view of the fact that the manufacturer discontinued a compassionate access programme on 30 June 2016; and if he will make a statement on the matter. [8873/17]

   Source: written

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products Reimbursement

  xml · EN · 22 February 2017

  ViewDownloadOpen at official source

Sponsors

• Grealish, Noel. · Asking member
• Health · Health · Addressed to

Related records

No cross-record relationships stored yet.